### Accepted Manuscript

Preliminary Communications\$Communications

Antifungal activity of 1'-homo-*N*-1,2,3-triazol-bicyclic carbonucleosides: a novel type of compound afforded by azide-enolate (3+2) cycloaddition

Davir González-Calderón, María G. Mejía-Dionicio, Marco A. Morales-Reza, José G. Aguirre-de Paz, Alejandra Ramírez-Villalva, Macario Morales-Rodríguez, Aydeé Fuentes-Benítes, Carlos González-Romero





Please cite this article as: D. González-Calderón, M.G. Mejía-Dionicio, M.A. Morales-Reza, J.G. Aguirre-de Paz, A. Ramírez-Villalva, M. Morales-Rodríguez, A. Fuentes-Benítes, C. González-Romero, Antifungal activity of 1'-homo-*N*-1,2,3-triazol-bicyclic carbonucleosides: a novel type of compound afforded by azide-enolate (3+2) cycloaddition, *Bioorganic Chemistry* (2016), doi: http://dx.doi.org/10.1016/j.bioorg.2016.09.003

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

#### **Short Communication**

# Antifungal activity of 1'-homo-*N*-1,2,3-triazol-bicyclic carbonucleosides: a novel type of compound afforded by azide-enolate (3+2) cycloaddition

Davir González-Calderón,<sup>a,\*</sup> María G. Mejía-Dionicio,<sup>a</sup> Marco A. Morales-Reza,<sup>a</sup> José G. Aguirre-de Paz,<sup>a</sup> Alejandra Ramírez-Villalva,<sup>a</sup> Macario Morales-Rodríguez,<sup>b</sup> Aydeé Fuentes-Benítes,<sup>a</sup> and Carlos González-Romero,<sup>a,\*</sup>

<sup>a</sup> Departamento de Química Orgánica, Facultad de Química, Universidad Autónoma del Estado de México, Paseo Colón/Paseo Tollocan s/n, Toluca, Estado de México, 50120, Mexico.

\* *Corresponding author*: Tel: +52 722 217 5109x113; Fax: +52 722 217 3890; e-mail: cgonzalezr@uaemex.mx (C. González-Romero) and qfb\_dgonzalez@yahoo.com.mx (D. González-Calderón).

#### Abstract

The first report of 1'-homo-*N*-1,2,3-triazol-bicyclic carbonucleosides (**7a** and **7b**) is described herein. Azide-enolate (3+2) cycloaddition afforded the synthesis of this novel type of compound. Antifungal activity was evaluated *in vitro* against four filamentous fungi (*Aspergillus fumigatus, Trichosporon cutaneum, Rhizopus oryzae* and *Mucor hiemalis*) as well as nine species of *Candida spp*. as yeast specimens. These pre-clinical studies suggest that compounds **7a** and **7b** are promising candidates for complementary biological studies due to their good activity against *Candida spp*.

**Keywords**: 1'-Homonucleosides; 1,2,3-Triazole; Antifungal activity; Azide-enolate cycloaddition

#### 1. Introduction

The chemistry and biology of nucleoside analogues has consolidated a very particular and proper field of study in organic and medicinal chemistry.[1] A certain classification of such compounds, convenient for the purpose of the present study, is described in Fig. 1. One of the most important modifications of nucleosides Aa[2] has been the replacement of the oxygen atom of the furanose ring with a methylene group, resulting in carbocyclic nucleosides Ab[3] (also called 'carbonucleosides' in short form). The recognition of 1,2,3-triazole scaffolds as potent pharmacophores[4] has revolutionized nucleoside analogs allowing for their conversion to the corresponding triazole derivatives **Ba**[5] and **Bb**.[6]

<sup>&</sup>lt;sup>b</sup> Departamento de Microbiología, Facultad de Química, Universidad Autónoma del Estado de México, Paseo Colón/Paseo Tollocan s/n, Toluca, Estado de México, 50120, Mexico.



**Fig. 1**. General classification of nucleoside analogues reported in literature. Possible positions (i, ii, and iii) for bicyclic derivatives E and F are known. A novel type of compound G is herein proposed.

1'-Homonucleosides (**Ca**[7] and **Cb**[8]) are a special class of modified nucleosides, in which the nucleobase (Het) and the sugar moiety (at its 1'-position) are separated by a carbon bridge. In addition to greater conformational flexibility and rotational freedom, this gives them more resistance to hydrolytic or enzymatic cleavage compared to the relatively reactive aminal linkage of common nucleosides.[9] Modified triazolic nucleosides **D**[10] can be found in literature, and the discovery of certain natural bicyclic nucleosides **Ea**[11] (*e.g.* Ezomycin[12] and Octosyl[13]) along with their potent antifungal activity[14] has sparked new research into the design and synthesis of novel carbonucleoside derivatives **Eb**[15] as well as their 1'-homo mimetics **F**.[16]

Sesquiterpene lactones (carbobicyclic lactones) are amongst the most abundant natural products. More than 8000 structures have been reported, [17] and they have broad structural and functional diversity including their antifungal activity [*e.g.* Sclareolide[18] (Fig. 2)]. The introduction of these scaffolds to nucleosides analogs (**H** and **I**) has been performed by Castillón.[19] The chemical structure of certain antifungal nucleoside analogs (**J**[20] and **K**<sup>[21]</sup> among others[22]) has inspired the design and synthesis of 1'-homo-*N*-1,2,3-triazol-bicyclic carbonucleosides **7a** and **7b**. To the best of our knowledge, this type of compound (**G**) has not yet been reported.



FIGURE 2. The current antifungal compounds Sclareolide, J and K as well as H and I inspired the design of novel nucleoside analogs 7a and 7b.

#### 2. Results and discussion

#### 2.1 Chemistry

The Cu-catalyzed azide-alkyne cycloaddition (CuAAC) has largely been the conventional approach for synthesizing triazole nucleosides. [5] In recent years, azide-enolate (3+2) cycloaddition (AEC) has emerged as a novel and potent tool for the synthesis of 1,2,3-triazole moieties. [23] As a pioneering strategy we describe the synthesis of **7a** and **7b** afforded by a versatile AEC (Scheme 1).

Our initial study began by obtaining silylated 'Corey lactone' **2**, according to our previous report, [24] as the key precursor for the present synthesis. This compound is an excellent supplier of the pseudosugar ring (cyclopentane) required for the highly stereospecific configuration of all suitable functional groups. A convenient protection–deprotection strategy for alcohols was planned for the present study involving the esterification of **2** with *p*-phenylbenzoyl chloride (PBCl) in dichloromethane and pyridine to form the ester lactone **3**.



**SCHEME 1**. *Reagents and conditions*: (i) PBCl (1.1 eq), Py anh., DCM, r.t., N<sub>2</sub>, 1 h, 90%. (ii) AlCl<sub>3</sub>·6H<sub>2</sub>O cat, MeOH, 60 °C, 12 h, 93%. (iii) PPh<sub>3</sub> (2.5 eq), I<sub>2</sub> (2.0 eq.), Im (2.5 eq.), MeCN anh., 80 °C, N<sub>2</sub>, 3 h, 85% (iv) For **6a**: NaN<sub>3</sub> (1.1 eq), DMF anh., 60 °C, N<sub>2</sub>, 6 h, then acetylacetone (1.1 eq), DBU (1.1 eq), 12 h, 60 °C, 72%. For **6b**: NaN<sub>3</sub> (1.1 eq), DMF anh, 60 °C, N<sub>2</sub>, 6 h, then 2-benzoylacetophenone (1.1 eq), DBU (1.1 eq), DBU (1.1 eq), DBU (1.1 eq), 12 h, 60 °C, 67%. (v) Both **7a** and **7b**: DBN cat, MeOH, r.t. 12 h, 87% and 81% respectively.

Previously,[25] we investigated the AlCl<sub>3</sub>·6H<sub>2</sub>O cleavage of silyl ethers in methanol. Thus, desilylation of **3** was accomplished by such a protocol to afford alcohol **4**, which was functionalized to the corresponding iodide derivative **5** according to the Garegg-Samuelsson procedure (PPh<sub>3</sub>/I<sub>2</sub>/Im/ROH system).[26] On the other hand, we recently[27] published a straightforward approach to the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles by the coupling of three-components (alkyl halides, sodium azide, and ketones) through an AEC. This method proved to be a very rapid and *elegant* way to access triazole building blocks **6a** and **6b** by the coupling of acetylacetone and 2benzoylacetophenone, respectively. Finally, transesterification of **6a** and **6b** by treatment with DBN in MeOH gave the corresponding carbonucleosides **7a** and **7b**.

Compounds **7a** and **7b** were evaluated for their *in vitro* antifungal activity against four filamentous fungi (*Aspergillus fumigatus* ATCC-16907, *Trichosporon cutaneum* ATCC-28592, *Rhizopus oryzae* ATCC-10329 and *Mucor hiemalis* ATCC-8690), as well as *Candida utilis* ATCC-9226, *Candida albicans* ATCC-10231 and *Candida tropicalis* ATCC-13803 as yeast specimens. In addition, other strains for *Candida spp*. (*C. lipolytica*, *C. pseudotropicalis*, *C. krusei*, *C. parapsilosis*, *C. glabrata*, and *Candida famata*) were collected from inpatients and evaluated under the aforementioned

protocol. CLSI standardized methods were employed to carry out the microbiological tests. We used the M38-A2[28] microdilution method to determine the sensitivity of filamentous fungi, and the M27-A3[29] method for *Candida* yeasts. The antifungal activity of compounds **7a** and **7b** was compared with itraconazole, a standard antifungal drug. The minimum inhibitory concentration (MIC) values of compounds and standard drugs, expressed in micrograms per milliliter, were determined in 96-well plates by using RPMI 1640 medium buffered with MOPS (3-[N-morpholino]propane sulfonic acid; Sigma-Aldrich).

#### 2.2 Antifungal activity

The antifungal activity of the evaluated compounds is summarized in Table 1. Compounds **7a** and **7b** showed good activity in some of the yeast strains, including *C*. *utilis, C. lipolytica, C. glabrata* and *C. famata,* demonstrating 'sensitivity'<sup>\*</sup> according to the parameters of document M27-A3 (Table 2). Only slight antifungal activity against *C. albicans, C. tropicalis, C. pseudotropicalis, C. krusei,* and *C. parapsilosis* was observed. Whereas there was evident resistance by *M. hiemalis,* slight activity was found against the rest of the filamentous fungi tested (*A. fumigatus, T. cutaneum, and R. oryzae*).

	Yeast fungi								Filamentous fungi				
Comp.	C. alb.	C. trop.	C. uti.	C. lipo.	C. pseu.	C. kru.	C. para.	C. gla.	C. fam.	M. hie.	A. fum.	T. cut.	R. ory.
1	0.25	0.5	0.12	0.12	0.5	4	2	0.5	0.06	>16	4	8	4
2	2	2	0.12	0.12	1	4	4	0.5	0.5	>16	8	>16	8
Standard <sup>a</sup>	0.03	0.25	0.25	0.03	0.12	0.25	0.12	0.06	0.06	4	0.5	2	1

Table 1. In vitro antifungal activities of synthetized compounds (MIC,  $\mu$ g/mL).

Abbreviations: C. alb., Candida albicans; C. trop., Candida tropicalis; C. uti., Candida utilis; C. lipo., Candida lipolytica; C. pseu., Candida pseudotropicalis; C. kru., Candida krusei; C. para., Candida parapsilosis; C.gla., Candida glabrata; C.fam., Candida famata; M. hie., Mucor hiemalis; A. fum., Aspergillus fumigatus; T. cut., Trichosporon cutaneum; R. ory., Rhizopus oryzae;

<sup>a</sup> Itraconazole

<sup>&#</sup>x27;S', 'SDD' and 'R' are represented by standardized values (breakpoints) used to appreciate the clinical value of the *in vitro* antifungal testing result and predicting the response of patients infected. Sensitivity is dependent on achieving the maximum dosages in plasma (breakpoints) to obtain optimal response. For itraconazole, an MIC within the susceptible-dose dependent (SDD) range indicates the need for plasma concentrations 0.25-0.5  $\mu$ g/mL for an optimal response. Actual breakpoints are described in Table 4 (See ref. 29b).

Compound	C. alb.	C. trop.	C. uti.	C. lipo.	C. pseu.	C. kru.	C. para.	C. gla.	C. fam.		
1	SDD	SDD	S	S	SDD	R	R	SDD	S		
2	R	R	S	S	R	R	R	SDD	SDD		
Standard <sup>a</sup>	S	SDD	SDD	S	S	SDD	S	S	S		
<i>a</i> – <i>i</i>	-										

**Table 2.** Sensitivity of yeast strains according to the document M27-A3: Susceptible (S), dose dependent sensitive (SDD) and resistant (R).

<sup>*a*</sup> Itraconazole. Interpretive criteria: Breakpoints (MIC,  $\mu$ g/mL) = 0.12 [S], 0.25–0.5 [SDD], 1 [R].

#### **3.** Conclusion

In conclusion, we report the first synthesis of a novel type of compound, represented by 1'-homo-*N*-1,2,3-triazol-bicyclic carbonucleosides **7a** and **7b**, which showed good activity against some of the yeast strains tested. Moreover, AEC was employed as a synthetic strategy. These advances make the present study a breakthrough in the field of nucleoside chemistry. The pre-clinical study of these compounds show a good antifungal scope for *Candida spp.*, representing new leads for further development of pharmacomodulator in this series.

#### 4. Experimental

#### 4.1 General

The reagents were purchased from Aldrich Chemical Co. and were used without further purification. Dichloromethane, pyridine, acetonitrile, and dimethylformamide were dried according to literature.[30] **Flash column chromatography**: SiO<sub>2</sub> 60 (230–400 mesh). **TLC**: Silica-gel plates (SiO<sub>2</sub>; 0.20-mm thickness); visualization with UV light at 254 nm or by staining with base soln. of CoCl<sub>2</sub>/H<sub>2</sub>SO<sub>4</sub> ac. (2g/100 mL H<sub>2</sub>SO<sub>4</sub> 10%) followed by heating ~140 °C. **m.p.**: *Fischer-Johns Scientific* melting point apparatus; uncorrected. <sup>1</sup>**H- and** <sup>13</sup>**C-NMR spectra**: *Bruker Avance 300 MHz* and a *Varian 500 MHz*;  $\delta$  in ppm rel. to Me<sub>4</sub>Si as internal standard, *J* in Hz. **MS**: *Shimadzu GCMS-QP2010 Plus*; in *m/z* (rel. %).

**4.1.1.** (3a*R*,4*S*,5*R*,6a*S*)-4-((*tert*-butyldimethylsilyloxy)methyl)-2-oxo hexahydro-2*H*-cyclopenta[*b*]furan-5-yl biphenyl-4-carboxylate (3). To a solution of Corey lactonealcohol **2** (2.0 g, 6.98 mmol) in anhydrous dichloromethane (DCM, 15.0 mL) and anhydrous pyridine (Py, 5.0 mL) at room temperature under inert atmosphere was added *p*-phenylbenzoyl chloride (1.66 g, 7.68 mmol). The reaction mixture was stirred for 1 h,

and then water (~70 mL) was added to the reaction mixture and washed with DCM (3×10 mL). In order to remove the excess Py, the organic layer was washed with CuSO<sub>4</sub> 5% sol. (5–8×20 mL until strong blue color of watery layer gradually turned to slightly blue color). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvent was concentrated in *vacuo*. The crude product was purified by flash column chromatography to give the white solid **3** (2.94 g, 90%). m.p. 91–95 °C. R<sub>f</sub>: 0.35 (Hex/EtOAc 8:2). <sup>1</sup>H NMR: (300 MHz, CDCl<sub>3</sub>)  $\delta$  = 8.06 (d, *J*= 8.4 Hz, 2 Ar-H), 7.64 (dd, *J*= 15.7, 7.7 Hz, 4 Ar-H), 7.49–7.33 (m, 3 Ar-H), 5.37 (dt, *J*= 5.8, 2.9 Hz, 1 H), 5.09 (t, *J*= 5.9 Hz, 1 H), 3.72 (qd, *J*= 10.2, 4.7 Hz, 2 H), 3.00–2.86 (m, 2 H), 2.65–2.42 (m, 2 H), 2.34 (d, *J*= 17.2 Hz, 2 H), 0.90 (s, 9 H), 0.07 (s, 6 H) ppm. <sup>13</sup>C NMR: (75 MHz, CDCl<sub>3</sub>)  $\delta$  = 176.86 (C=O), 165.86 (C=O), 145.84 (C), 139.92 (C), 130.14 (2 CH), 128.89 (2 CH), 128.52 (C), 128.12 (CH), 127.24 (2 CH), 127.12 (2 CH), 85.42 (CH), 78.78 (CH), 63.43 (CH<sub>2</sub>), 55.16 (CH), 40.53 (CH), 39.07 (CH<sub>2</sub>), 36.24 (CH<sub>2</sub>), 25.84 (3 CH<sub>3</sub>), 18.17 (C), -5.53 (2 CH<sub>3</sub>) ppm. MS-EI<sup>+</sup> m/z (%): 409 [C<sub>23</sub>H<sub>25</sub>O<sub>5</sub>Si<sup>+</sup>] (20), 256 (100), 211 (69), 182 (76), 152 (90), 127 (23), 91 (20), 75 (43), 57 [C<sub>4</sub>H<sub>9</sub><sup>+</sup>] (20).

**4.1.2.(3a***R*,**4***S*,**5***R*,**6a***S*)-**4**-(hydroxymethyl)-2-oxohexahydro-2*H*-cyclopenta [*b*]furan-**5-yl biphenyl-4-carboxylate (4).** To a solution of silyl ether **3** (2.0 g, 4.29 mmol) in methanol (18.0 mL) was added a catalytic amount of AlCl<sub>3</sub>·6H<sub>2</sub>O (0.05 g, 0.2 mmol). The reaction mixture was stirred at 60 °C for 12 h. The solvent was removed under reduced pressure. The crude product was purified by flash column chromatography affording a white solid **4** (1.4 g, 93%). m.p. 147–150 °C. R<sub>f</sub>: 0.3 (Hex/EtOAc 2:8). <sup>1</sup>H NMR: (300 MHz, CDCl<sub>3</sub>+(CD<sub>3</sub>)<sub>2</sub>SO)  $\delta$  = 8.04 (d, *J*= 8.4 Hz, 2 Ar-H), 7.63 (dd, *J*= 14.3, 7.6 Hz, 4 Ar-H), 7.50–7.33 (m, 3 Ar-H), 5.43 (dt, *J*= 5.5, 2.7 Hz, 1 H), 5.10 (t, *J*= 5.7 Hz, 1 H), 4.55 (t, *J*= 5.1 Hz, 1 H), 3.60 (td, *J*= 5.4, 3.2 Hz, 2 H), 3.01–2.86 (m, 2 H), 2.65–2.38 (m, 2 H), 2.38–2.26 (m, 2 H) ppm. <sup>13</sup>C NMR: (75 MHz, CDCl<sub>3</sub>+(CD<sub>3</sub>)<sub>2</sub>SO)  $\delta$ = 177.00 (C=O), 165.53 (C=O), 145.43 (C), 139.52 (C), 129.99 (2 CH), 128.86 (2 CH), 128.56 (C), 128.11 (CH), 127.02 (2 CH), 126.85 (2 CH), 85.10 (CH), 78.47 (CH), 61.99 (CH<sub>2</sub>), 55.26 (CH), 40.14 (CH), 38.44 (CH<sub>2</sub>), 36.21 (CH<sub>2</sub>), ppm. MS-EI<sup>+</sup> m/z (%): 353 [M<sup>+</sup>+1] (73), 200 (100), 183 (82), 180 (31), 151 (64), 125 (53), 79 (25), 41 (35).

**4.1.3.** (3a*R*,4*R*,5*R*,6a*S*)-4-(iodomethyl)-2-oxohexahydro-2*H*-cyclopenta [*b*]furan-5yl biphenyl-4-carboxylate (5). To a solution of alcohol **4** (2.0 g, 5.68 mmol), triphenylphosphine (3.72 g, 14.19 mmol), and imidazole (0.96 g, 14.19 mmol) in

anhydrous acetonitrile (35.0 mL) was added I<sub>2</sub> (2.88 g, 11.35 mmol). The solution was stirred for 3 h at 80 °C under nitrogen atmosphere. After this time, the reaction mixture was added to brine (~150 mL) and washed with EtOAc (3×30 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent was evaporated under reduced pressure. The crude was purified by flash column chromatography to afford the white solid **5** (2.2 g, 85%). m.p. 142–145 °C. R<sub>f</sub>: 0.4 (Hex/EtOAc 6:4). <sup>1</sup>H NMR: (300 MHz, CDCl<sub>3</sub>)  $\delta$  = 8.06 (d, *J* = 8.4 Hz, 2 Ar-H), 7.76–7.33 (m, 7 Ar-H), 5.33–5.23 (m, 1 H), 5.07 (td, *J* = 6.4, 1.8 Hz, 1 H), 3.36 (dd, *J* = 10.3, 5.2 Hz, 1 H), 3.22 (dd, *J* = 10.3, 7.7 Hz, 1 H), 2.95 (dd, *J* = 17.8, 10.1 Hz, 1 H), 2.87–2.76 (m, 1 H), 2.66–2.49 (m, 2 H), 2.46–2.27 (m, 2 H) ppm. <sup>13</sup>C NMR: (75 MHz, CDCl<sub>3</sub>)  $\delta$  = 176.11 (C=O), 165.65 (C=O), 146.02 (C), 139.72 (C), 130.19 (2 CH), 128.90 (2 CH), 128.20 (CH), 127.99 (C), 127.21 (2 CH), 127.12 (2 CH), 83.71 (CH), 79.45 (CH), 54.05 (CH), 44.28 (CH), 37.86 (CH<sub>2</sub>), 35.72 (CH<sub>2</sub>), 7.03 (CH<sub>2</sub>-I) ppm. MS-EI<sup>+</sup> m/z (%): 463 [M+1]<sup>+</sup> (78), 335 (21), 277 (74), 200 (76), 180 (100), 154 (77), 127 (41), 109 (40), 91 (89), 77 (87), 54 (73), 39 (56).

4.1.4. (3aR,4S,5R,6aS)-4-((4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)methyl)-2oxohexahydro-2*H*-cyclopenta[*b*]furan-5-yl biphenyl-4-carboxylate (6a). The alkyl halide 5 (1.0 g, 2.16 mmol) and sodium azide (0.16 g, 2.38 mmol) were added to anhydrous dimethylformamide (17.0 mL). The reaction mixture was stirred at 60 °C for 6 h under nitrogen atmosphere. After this time, TLC indicated the disappearance of the starting material. Then, acetylacetone (0.24 mL, 2.38 mmol) and DBU (0.36 mL, 2.38 mmol) were added to the reaction mixture which was stirred for 12 h at 60 °C. Brine (~100.0 mL) was added to the reaction mixture and washed with EtOAc (3×30 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent evaporated under reduced pressure. Flash column chromatography afforded the yellow solid 6a (0.71 g, 72%). m.p. 56–60°C. R<sub>f</sub>: 0.4 (Hex/EtOAc 3:7). <sup>1</sup>H NMR: (300 MHz, CDCl<sub>3</sub>)  $\delta = 8.05-7.95$ (m, 2 Ar-H), 7.72–7.56 (m, 4 Ar-H), 7.54–7.35 (m, 3 Ar-H), 5.32–5.20 (m, 1 H), 5.18– 5.07 (m, 1 H), 4.55–4.30 (m, 2 H), 3.07–2.95 (m, 1 H), 2.93–2.78 (m, 1 H), 2.77–2.52 (m, 8 H), 2.45–2.21 (m, 2 H), 1.45–1.11 (m, 1 H), 0.97–0.82 (m, 1 H) ppm. <sup>13</sup>C NMR:  $(75 \text{ MHz}, \text{CDCl}_3) \delta = 194.03 \text{ (C=O)}, 175.66 \text{ (C=O)}, 165.69 \text{ (C=O)}, 146.27 \text{ (C)}, 143.67 \text{$ (C), 139.61 (C), 136.81 (C), 130.11 (2 CH), 128.91 (2 CH), 128.26 (CH), 127.48 (C), 127.19 (2 CH), 127.15 (2 CH), 83.26 (CH), 77.13 (CH), 51.66 (CH<sub>2</sub>), 48.57 (CH), 41.21 (CH), 37.68 (CH<sub>2</sub>), 35.33 (CH<sub>2</sub>), 27.58 (CH<sub>3</sub>), 9.09 (Ar-CH<sub>3</sub>) ppm. MS-EI<sup>+</sup> m/z (%): 459 [M<sup>+</sup>], 181 (15), 149 (14), 91 (12), 71 (22), 57 (42), 48 (100), 41 (50).

4.1.5. (3a*R*,4*S*,5*R*,6a*S*)-4-((4-benzoyl-5-phenyl-1*H*-1,2,3-triazol-1-yl) methyl)-2oxohexahydro-2*H*-cyclopenta[*b*]furan-5-yl biphenyl-4-carboxylate (6b). The alkyl halide 5 (1.0 g, 2.16 mmol) and sodium azide (0.16 g, 2.38 mmol) were added to anhydrous dimethylformamide (17.0 mL). The reaction mixture was stirred at 60 °C for 6 h under nitrogen atmosphere. After this time, TLC indicated the disappearance of the starting material. Then, 2-benzoylacetophenone (0.54 g, 2.38 mmol) and DBU (0.36 mL, 2.38 mmol) were added to the reaction mixture which was stirred for 12 h at 60 °C. Brine (~100.0 mL) was added to the reaction mixture and washed with EtOAc (3×30 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent evaporated under reduced pressure. Flash column chromatography afforded the slightly yellow solid 6b (0.84 g, 67%). m.p. 71–76 °C. R<sub>f</sub>: 0.55 (Hex/EtOAc 3:7). <sup>1</sup>H NMR: (500 MHz, CDCl<sub>3</sub>)  $\delta$  = 8.24-8.22 (m, 1 Ar-H), 8.22-8.21 (m, 1 Ar-H), 7.93 (d, J= 2.0 Hz, 1 Ar-H), 7.91 (d, J= 2.0 Hz, 1 Ar-H), 7.65–7.64 (m, 1 Ar-H), 7.63–7.62 (m, 1 Ar-H), 7.61–7.59 (m, 1 Ar-H), 7.61-7.56 (m, 1 Ar-H), 7.58-7.55 (m, 1 Ar-H), 7.53-7.49 (m, 3 Ar-H), 7.50-7.45 (m, 2 Ar-H), 7.48–7.43 (m, 2 Ar-H), 7.46–7.39 (m, 3 Ar-H), 5.16–5.12 (m, 1 H), 5.01 (td, J= 6.5, 2.2 Hz, 1 H), 4.53 (dd, J= 14.1, 6.9 Hz, 1 H), 4.44 (dd, J= 14.2, 7.7 Hz, 1 H), 2.84– 2.79 (m, 2 H), 2.63–2.52 (m, 2 H), 2.28–2.21 (m, 1 H), 2.19–2.13 (m, 1 H) ppm. <sup>13</sup>C NMR:  $(125 \text{ MHz}, \text{CDCl}_3) \delta = 186.10 \text{ (C=O)}, 175.55 \text{ (C=O)}, 165.50 \text{ (C=O)}, 146.22 \text{ (C)}, 146.$ 143.82 (C), 141.93 (C), 139.71 (C), 136.83 (C), 133.14 (C), 130.61 (2 CH<sub>2</sub>), 130.37 (CH), 130.15 (2 CH<sub>2</sub>), 129.54 (2 CH<sub>2</sub>), 129.16 (2 CH<sub>2</sub>), 128.93 (2 CH<sub>2</sub>), 128.28 (C), 128.25 (2 CH<sub>2</sub>), 127.58 (CH), 127.27 (2 CH<sub>2</sub>), 127.14 (2 CH<sub>2</sub>), 125.90 (CH), 82.91 (CH), 77.21 (CH), 51.59 (CH<sub>2</sub>), 49.21 (CH), 41.11 (CH), 37.61 (CH<sub>2</sub>), 35.12 (CH<sub>2</sub>) ppm.

**4.1.6.** (3a*R*,4*S*,5*R*,6a*S*)-4-((4-acetyl-5-methyl-1*H*-1,2,3-triazol-1-yl)methyl)-5hydroxyhexahydro-2*H*-cyclopenta[*b*]furan-2-one (7a). To a solution of ester 6a (0.6 g, 1.31mmol) in MeOH (5.0 mL) was added a catalytic amount of DBN (0.008 mL, 0.065 mmol). The reaction mixture was stirred at room temperature for 12 h. Then solvent was removed under reduced pressure. The crude was purified by flash column chromatography to give the thick yellow oil 7a (0.32 g, 87%). **R**<sub>f</sub>: 0.3 (Hex/EtOAc 5:95). <sup>1</sup>H NMR: (500 MHz, CDCl<sub>3</sub>)  $\delta$  = 4.94 (td, *J*= 6.8, 3.1 Hz, 1 H), 4.42–4.29 (m, 2 H), 4.03 (q, *J*= 6.8 Hz, 1 H), 2.79–2.72 (m, 2 H), 2.69 (s, 3 H), 2.61 (s, 3 H), 2.51 (dt, *J*= 14.9, 6.8 Hz, 1 H), 2.30 (p, *J*= 7.0 Hz, 1 H), 2.26–2.17 (m, 2 H), 2.05 (ddd, *J*= 14.9,

6.8, 3.2 Hz, 1 H) ppm. <sup>13</sup>C NMR: (125 MHz, CDCl<sub>3</sub>)  $\delta$  = 194.17 (C=O), 176.19 (C=O), 143.68 (C), 137.03 (C), 82.13 (CH), 74.36 (CH), 52.68 (CH<sub>2</sub>), 48.08 (CH), 40.51 (CH<sub>2</sub>), 40.34 (CH), 34.66 (CH<sub>2</sub>), 27.72 (CH<sub>3</sub>), 9.13 (CH<sub>3</sub>) ppm. **MS-EI<sup>+</sup> m/z** (%): 279 [M<sup>+</sup>] (20), 167 (77), 148 (35), 127 (84), 112 (32), 85 (85), 70 (87), 55 (81), 41 (83).

**4.1.7.** (3a*R*,4*S*,5*R*,6a*S*)-4-((4-benzoyl-5-phenyl-1*H*-1,2,3-triazol-1-yl) methyl)-5hydroxyhexahydro-2*H*-cyclopenta[*b*]furan-2-one (7b). This compound was prepared from 6b (0.7 g, 1.2 mmol) according to the synthetic procedure for 7a. The crude was purified by flash column chromatography to afford the thick yellow oil 7b (0.392 g, 81%). R<sub>f</sub>: 0.35 (Hex/EtOAc 1:9). <sup>1</sup>H NMR: (500 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.96–7.93 (m, 3 Ar-H), 7.69–7.66 (m, 1 Ar-H), 7.64–7.61 (m, 1 Ar-H), 7.50–7.42 (m, 5 Ar-H), 3.57–3.51 (m, 2 H), 3.48–3.41 (m, 3 H), 3.40–3.35 (m, 3 H), 2.63–2.57 (m, 2 H), 2.18 (s, 1 OH), 1.80–1.75 (m, 1 H) ppm. <sup>13</sup>C NMR: (125 MHz, CDCl<sub>3</sub>)  $\delta$  = 177.34 (C=O), 166.93 (C=O), 143.88 (C), 140.33 (C), 134.53 (C), 131.16 (2 CH), 128.84 (2 CH), 128.47 (2 CH), 127.60 (C), 127.20 (CH), 127.16 (CH), 127.07 (2 CH), 77.42 (CH), 77.22 (CH), 49.62 (CH<sub>2</sub>), 45.00 (CH), 37.15 (CH), 35.31 (2 CH), 29.96 (CH<sub>2</sub>) ppm. MS-EI<sup>+</sup> m/z (%): 351 [C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>"] (38), 52 [C<sub>4</sub>H<sub>4</sub>"] (14), 183 [C<sub>8</sub>H<sub>4</sub>N<sub>2</sub>O<sub>3</sub>"] (72), 276 (80), 246 (22), 199 (90), 152 (88), 127 (100), 99 (60), 69 (80), 55 (97).

#### Acknowledgments

Financial support from SIEA-UAEMex (project No. 3804/2014/CID) and CONACYT-Mexico (postgraduate scholarship No. 227581 and No. 273644) is gratefully acknowledged. The authors would like to thank the referee for valuable comments and suggestions, Signa S.A. de C.V. for some graciously donated solvents and reagents, M.N. Zavala-Segovia and L. Triana-Cruz (CCIQS UAEMex–UNAM) for technical support.

#### References

(1)(a) P. Merino, (Ed.) Chemical Synthesis of Nucleoside Analogues, John Wilev & Sons, Inc., Hoboken, NJ, USA. 2013. DOI: 10.1002/9781118498088. (b) L. H. Zhang, Z. Xi, J. Chattopadhyaya (Eds.) Medicinal Chemistry of Nucleic Acids, John Wiley & Sons, Inc., Hoboken, NJ, USA. 2011. DOI: 10.1002/9781118092804. (c) C. Simons, Nucleoside Mimetics: Their Chemistry and Biological Properties, Taylor & Francis Ltd, 2000, ISBN-13: 9789056993245. (d) C. K. Chu, (Ed.), Recent Advances in Nucleosides: Chemistry and Chemotherapy. Elsevier Science B.V., 2002, ISBN: 978-0-444-50951-2.

- (2) (a) U. Pradere, E. C. Garnier-Amblard, S. J. Coats, F. Amblard, R. F. Schinazi, Chem. Rev.114 (2014), 9154–9218. (b) P. Clivio, S. Coantic-Castex, D. Guillaume, Chem. Rev. 113 (2013), 7354–7401. (c) T. Pathak, Chem. Rev. 102, (2002), 1623-1667. (d) A. Mieczkowski, V. Roy, L. A Agrofoglio, Chem. Rev. 110 (2010), 1828–1856. (e) J. Štambaský, M. Hocek, P. Kočovský, Chem. Rev. 109, (2009), 6729–6764. (f) L. A. Agrofoglio, I. Gillaizeau, Y. Saito, Chem. Rev. 103, (2003), 1875-1916. (g) J. S. Cooperwood, G. Gumina, F. D. Boudinot, C. K. Chu, Nucleoside and Nucleotide Prodrugs, in: Recent Advances in Nucleosides: Chemistry and Chemotherapy. C. K. Chu (Ed.), Elsevier Science B.V., 2002, doi:10.1016/B978-044450951-2/50005-9.
- (a) E. S. Matyugina, A. L. Khandazhinskaya, Russ. Chem. Bull. Int. Ed. 63, (3) (2014), 1069–1080. (b) O. Boutureira, M. I. Matheu, Y. Díaz, S. Castillón, Chem. Soc. Rev. 42, (2013), 5056-5072. (c) E. Leclerc, Chemical Synthesis of Carbocyclic Analogues of Nucleosides, in: Chemical Synthesis of Nucleoside Analogues, P. Merino (Ed), John Wiley & Sons, Inc., Hoboken, NJ, USA. 2013. doi: 10.1002/9781118498088.ch12. (d) J. Wang, R. K. Rawal, C. K. Chu, Recent Advances in Carbocyclic Nucleosides: Synthesis and Biological Activity, in: Medicinal Chemistry of Nucleic Acids. L. H. Zhang, Z. Xi, J. Chattopadhyaya (Eds.), John Wiley & Sons, Inc., Hoboken, NJ, USA. 2011. doi: 10.1002/9781118092804.ch1. (e) S. W. Schneller, K. L. Seley, V. R. Hegde, V. P. Rajappan, 5'-Norcarbanucleosides in L-Like Configurations, in: Recent Advances in Nucleosides: Chemistry and C. K. Chu, (Ed.), Chemotherapy. Elsevier Science B.V., 2002, doi:10.1016/B978-044450951-2/50009-6. (f) M. Ferrero, V. Gotor, Chem. Rev. 100, (2000), 4319-4347.
- (4) (a) F. de Carvalho da Silva, M. F. do Carmo Cardoso, P. Garcia-Ferreira, V. F. Ferreira, Biological Properties of 1*H* -1,2,3- and 2*H* -1,2,3-Triazoles, in: Chemistry of 1,2,3-triazoles. W. Dehaen, V. A. Bakulev, (Eds.), Springer International Publishing, Switzerland, 2015. DOI: 10.1007/7081\_2014\_124. (b) A. Massarotti, S. Aprile, V. Mercalli, E. Del Grosso, G. Grosa, G. Sorba, G. C. Tron, ChemMedChem 9 (2014), 2497–2508. (c) S. G. Agalave, S. R. Maujan, V. S. Pore, Chem. Asian J. 6 (2011), 2696–2718. (d) A. Lauria, R. Delisi, F. Mingoia, A. Terenzi, A. Martorana, G. Barone, A. M. Almerico, Eur. J. Org. Chem. (2014), 3289–3306. (e) P. Thirumurugan, D. Matosiuk, K. Jozwiak, Chem. Rev. 113, (2013), 4905–4979. (f) J. F. Lutz, Z. Zarafshani, Adv. Drug Deliv. Rev. 60 (2008), 958–970.
- (5) (a) F. Amblard, J. H. Cho, R. F. Schinazi, Chem. Rev. 109, (2009), 4207–4220. (b) W. Zou, M. Bhasin, K. Vembaiyan, D. T. Williams, Carbohydrate Res. 344 (2009), 1024–1027. (c) V. Aragao-Leoneti, V. L. Campo, A. S. Gomes, R. A. Field, I. Carvalho, Tetrahedron 66 (2010), 9475–9492.
- (6) (a) L. Kiss, E. Forró, R. Sillanpää, F. Fülöp, Tetrahedron 66, (2010), 3599–3607. (b) N. Joubert, R. F. Schinazi, L. A. Agrofoglio, Tetrahedron 61 (2005), 11744–11750. (c) J. H. Cho, D. L. Bernard, R. W. Sidwell, E. R. Kern, C. K. Chu, J. Med. Chem. 49 (2006), 1140–1148. (d) I. Pérez-Castro, O. Caamaño, F. Fernández, M. D. García, C. López, E. De Clercq, Org. Biomol. Chem. 5 (2007), 3805–3813. (e) Y. Saito, V. Escuret, D. Durantel, F.

Zoulim, R. F. Schinazi, L. A Agrofoglio, Bioorg. Med. Chem. 11 (2003), 3633–3639.

- (7) (a) U. Chiacchio, M. G. Saita, L. Crispino, G. Gumina, S. Mangiafico, V. Pistarà, G. Romeo, A. Piperno, E. De Clercq, Tetrahedron 62, (2006), 1171–1181. (b) C. L. Scremin, J. H. Boal, A. Wilk, L. R. Phillips, S. L. Beaucage, Bioorg. Med. Chem. Lett. 6 (1996), 207-212. (c) J. H. Boal, A. Wilk, C. L. Scremin, G. N. Gray, L. R. Phillips, S. L. Beaucage, J. Org. Chem. 61, (1996), 8617-8626. (d) N. Hossain, N. Blaton, O. Peeters, J. Rozenski, P. A. Herdewijn, Tetrahedron 52 (1996), 5563-5578. (e) M. W. Winkley, Carbohydrate Res. 31 (1973), 245-254.
- (8) (a) V. P. Rajappan, X. Yin, S. W. Schneller, Tetrahedron, 58 (2002), 9889-9895.
  (b) F. Abad, F. Álvarez, F. Fernández, X. García-Mera, J. E. Rodríguez-Borges, Nucleos. Nucleot. Nucleic acids 20 (2001) 1127–1128. (c) U. Dhuppad, V. Aravat, S. Navhat, A. Thomas, S. Kadam, (Glenmark Pharmaceuticals S.A., Switzerland). Pharmaceutical Containing Melogliptin Dipeptidyl Peptidase-IV Inhibitor. U.S. Pat. Appl. Publ. 2010, US 2010-683696; US 20100173964 A1, July 8, 2010; SciFinder Scholar: AN 2010:85194.
- (9) C. Lamberth, Org. Prep. Proc. Int. 34 (2002), 149-167.
- (a) A. Kayet, D. Datta, G. Kumar, A. Sundar, A. S. Ghosh, T. Pathak, RSC (10)Adv. 4 (2014), 63036-63038. (b) A. Kayet, T. Pathak, J. Org. Chem. 78 (2013), 9865-9875. (c) B. Bhatt, R. J. Thompson, M. von Itsztein, Tetrahedron Lett. 52 (2011), 2741–2743. (d) R. P. Tripathi, A. K. Yadav, A. Ajay, S. S. Bisht, V. Chaturvedi, S. K. Sinha, Eur. J. Med. Chem. 45 (2010), 142-148. (e) R. V. Somu, H. Boshoff, C. Qiao, E. M. Bennett, C. E. Barry III, C. C. Aldrich, J. Med. Chem. 49 (2006), 31-34. (f) A. Goeminne, M. McNaughton, G. Bal, G. Surpateanu, P. Van der Veken, S. De Prol, W. Versées, J. Steyaert, S. Apers, A. Haemers, K. Augustyns, Bioorg. Med. Chem. Lett. 17 (2007), 2523-2526. (g) P. Norris, D. Horton, B. R. Levine, Heterocycles 43 (1996), 2643-2655. (h) N. Singh, S. K. Pandey, R. P. Tripathi, Carbohydrate Res. (2010), 1641–1648. (i) D. R. da Rocha, W. C. Santos, E. S. Lima, V. F. Ferreira, Carbohydrate Res. 350 (2012), 14-19. (j) T. M. Potewar, K. T. Petrova, M. T. Barros, Carbohydrate Res. 379 (2013), 60-67.
- (11) (a) S. Hanessian, S. Marcotte, R. Machaalani, G. Huang, Org. Lett. 5, (2003), 4277–4280. (b) For a complete Review about synthetic bicyclic nucleosides see: J. Lebreton, J. M Escudier, L. Arzel, C. Len, Chem. Rev. 110 (2010), 3371–3418.
- (12) (a) K. Sakata, A. Bakurai, S. Tamura, Agric. Biol. Chem. 37 (1973), 697–699. (b) K. Sakata, A. Sakurai, S. Tamura, Agric. Biol. Chem. 39 (1975), 885–892.
- (13) (c) K. Isono, P. F. Crain, J. A. McCloskey, J. Am. Chem. Soc. 97 (1975), 943–945.
- (14) (a) S. Hanessian, G. Huang, C. Chenel, R. Machaalani, O. Loiseleur, J. Org. Chem. 70 (2005), 6721–6734. (b) A. Datta, Synthetic Studies on Antifungal Peptidyl Nucleoside Antibiotics, in Chemical Synthesis of Nucleoside Analogues, P. Merino (Ed.), John Wiley & Sons, Inc., Hoboken, NJ, USA. 2013. doi: 10.1002/9781118498088.ch18.
- (15) (a) D. C. Pryde, D. S. Middleton, P. T. Stephenson, P. Wainwright, A. Maddaford, X. Zhang, D. Leese, R. Glen, J. Hart, N. Forrest, T. Guyot,

Tetrahedron Lett. 52 (2011), 6415–6419. (b) M. J. Comin, D. A. Parrish, J. R. Deschamps, V. E. Marquez, Org. Lett. 8 (2006), 705-708. (c) B. Richichi, S. Cicchi, U. Chiacchio, G. Romeo, A. Brandi, Tetrahedron 59 (2003), 5231–5240.

- (16) N. R. Swamy, N. Suryakiran, P. P. Naidu, Y. Venkateswarlu, Carbohydrate Res. 352 (2012), 191–196.
- (17) (a) A. Santana, J. M. G. Molinillo, F. A. Macías, Eur. J. Org. Chem. (2015), 2093–2110. (b) B. M. Fraga, Nat. Prod. Rep. 29 (2012), 1334–1366.
- (18) M. I. Choudhary, S. G. Musharraf, A. Sami, Atta-ur-Rahman, Helv. Chim. Acta, 87 (2004), 2685–2694.
- (19) M. Kassou, S. Castillón, J. Org. Chem. 62 (1997), 3696–3701.
- (20) M. Ikbal, C. Cerceau, F. Le Goffic, S. Sicsic, Eur. J. Med. Chem. 24 (1989), 415-420.
- (21) L. V. R. Reddy, P. V. Reddy, N. N. Mishra, P. K. Shukla, G. Yadav, R. Srivastava, A. K. Shaw, Carbohydr. Res. 345 (2010), 1515–1521.
- (22) (a) C. S. Stauffer, A. W. Fothergill, M. G. Rinaldi, A. Dutta, Future Med. Chem. 1 (2009), 379-389. (b) X. Yin, G. Zhao, S. W. Schneller, Tetrahedron Lett. 48 (2007), 4809–4811. (c) C. S. Stauffer, P. Bhaket, A. W. Fothergill, M. G. Rinaldi, A. Datta, J. Org. Chem. 72 (2007), 9991-9997. (d) M. Winn, R. J. M. Goss, K. Kimura, T. D. H. Bugg, Nat. Prod. Rep. 27 (2010), 279– 304. (e) R. Srivastava, A. Bhargava, R. K. Singh, Bioorg. Med. Chem. Lett. 17 (2007), 6239–6244. (f) C. S. Stauffer, A. Datta, J. Org. Chem. 73 (2008), 4166–4174.
- (23) (a) C. G. S. Lima, A. Ali, S. S. van Berkel, B. Westermann, M. W. Paixão, Chem. Commun. 51, (2015), 10784-10796. (b) J. John, J. Thomas, W. Dehaen, Chem. Commun. 51 (2015), 10797-10806. (c) S. S. V. Ramasastry, Angew. Chem. Int. Ed. 53 (2014), 14310–14312.
- (24) C. A. González-González, A. Fuentes-Benítes, E. Cuevas-Yañez, D. Corona-Becerril, C. González-Romero, D. González-Calderón, Tetrahedron Lett. 54 (2013), 2726-2728.
- (25) D. González-Calderón, L. J. Benitez-Puebla, C. A. González-González, M. E. García-Eleno, A. Fuentes-Benítes, E. Cuevas-Yañez, D. Corona-Becerril, C. González-Romero, Synth. Commun. 44, (2014), 1258–1265.
- (26) P. J. Garegg, B. J. C. S. Samuelsson, J. Chem. Soc., Chem. Commun. (1979), 978–980.
- (27) D. González-Calderón, J. G. Aguirre-De Paz, C. A. González-González, A. Fuentes-Benítes, C. González-Romero, Tetrahedron Lett. 56 (2015), 1713–1715.
- (a) National Committee for Clinical Laboratory Standards Institute (CLSI), Document M38-A2: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Approved StandardeSecond Edition, Clinical and Laboratory Standards Institute, Wayne, PA, 2002; (b) A.L. Barry, An overview of the Clinical and Laboratory Standards Institute (CLSI) and its impact on antimicrobial susceptibility tests, in: R. Schwalbe, L. Steele-Moore, A.C. Goodwin (Eds.), Antimicrobial Susceptibility Testing Protocols, CRC Press Taylor & Francis Group, Florida, 2007, pp. 1-6. ISBN: 9780824741006. (c) A. Espinel-Ingroff, E. Canton, Antifungal susceptibility testing of filamentous fungi, in: R. Schwalbe, L. Steele-Moore, A.C. Goodwin (Eds.), Antimicrobial Susceptibility Testing Protocols, CRC Press Taylor & Francis Group, Florida, 2007, pp. 209-241. ISBN: 9780824741006.

- (29) (a) National Committee for Clinical and Laboratory Standards Institute (CLSI), M27-A3: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved StandardeThird Edition, Clinical and Laboratory Standards Institute, Wayne, PA, 2008. ISBN: 1-56238-666-2.
  (b) A. Espinel-Ingroff, E. Canton, Antifungal susceptibility testing of yeasts, in: R. Schwalbe, L. Steele-Moore, A.C. Goodwin (Eds.), Antimicrobial Susceptibility Testing Protocols, CRC Press Taylor & Francis Group, Florida, 2007, pp.173-208. ISBN: 9780824741006; (c) A.W. Fothergill, Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) methods, in: G.S. Hall (Ed.), Interactions of Yeasts, Moulds, and Antifungal Agents. How to Detect Resistance, Springer Science-Business Media, 2012, pp. 65-74, http://dx.doi.org/10.1007/978-1-59745-134-5\_2.
- (30) W.L.F. Armarego, C. Chai, Purification of Laboratory Chemicals, 7th Ed., Elsevier, Oxford, UK, 2013. ISBN-13: 978-0123821614

#### **Graphical Abstract**



### **Highlights**

- The first report of 1'-homo-N-1,2,3-triazol-bicyclic carbonucleosides as novel type of • compounds is described.
- The azide-enolate (3+2) cycloaddition afforded the synthesis of such compounds. •
- Good activities against Candida spp. for synthetized compounds •

por